Andy Chen
Stock Analyst at Wolfe Research
(1.79)
# 3,054
Out of 4,754 analysts
33
Total ratings
34.78%
Success rate
-6.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Initiates: Outperform | n/a | $14.64 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $34.14 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $8.88 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $9.91 | +101.82% | 1 | Feb 4, 2025 | |
| VERA Vera Therapeutics | Initiates: Outperform | $49 | $28.41 | +72.47% | 1 | Feb 4, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $19 | $6.64 | +186.14% | 1 | Feb 4, 2025 | |
| IMVT Immunovant | Downgrades: Peer Perform | n/a | $18.44 | - | 2 | Jan 3, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $697 | $622.61 | +11.95% | 2 | Nov 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Underperform | n/a | $243.53 | - | 2 | Nov 12, 2024 | |
| INCY Incyte | Initiates: Outperform | n/a | $70.26 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $19.35 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $39.71 | - | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $30.17 | +115.45% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $45.54 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $313.47 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.41 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $1.05 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $32.60 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $42.29 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.17 | +67.16% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $9.45 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $483.31 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $76.29 | -44.95% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $1.00 | +5,915.04% | 1 | Aug 8, 2023 |
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $14.64
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $34.14
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.88
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $9.91
Upside: +101.82%
Vera Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $28.41
Upside: +72.47%
Zenas BioPharma
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $6.64
Upside: +186.14%
Immunovant
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $18.44
Upside: -
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $622.61
Upside: +11.95%
Alnylam Pharmaceuticals
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $243.53
Upside: -
Incyte
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $70.26
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $19.35
Upside: -
Aug 26, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $39.71
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $30.17
Upside: +115.45%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $45.54
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $313.47
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $14.41
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $1.05
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $32.60
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $42.29
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $10.17
Upside: +67.16%
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $9.45
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $483.31
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $76.29
Upside: -44.95%
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $1.00
Upside: +5,915.04%